Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

By M. Roach, G. Hanks, Howard D. Thames, Paul Schellhammer, W. Shipley, G. Sokol, H. Sandler. International Journal of Radiation Oncology, Biology, Physics, 2006

2,746 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine, Radiation

View Paper: https://www.semanticscholar.org/paper/85407efa495599d687d54ce3517004330e2c819f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pulmonary and Respiratory Medicine

1. N. Mottet
2. Thomas Wiegel
3. Steven Joniau
4. J. Bellmunt
5. Michel Bolla
6. V. Matveev
7. F. Zattoni
8. A. Heidenreich

Citations in the corpus

• EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. (2017, methodology): “After primary radiation therapy (RT), the Radiation Therapy Oncology Group (RTOG) and American Society for Radiation Oncology Phoenix Consensus Conference definition of PSA failure is any PSA increase 2 ng/ml higher than the PSA nadir value, regardless of the serum concentration of the nadir [5].”
• Radiotherapy and short-term androgen deprivation for localized prostate cancer. (2011, neutral): “Almost never or never 54/349 (15) 44/344 (13) 0.”
• EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. (2011, methodology): “Following radiation therapy (RT), a PSA value of 2 ng/ml above the nadir after RT represents recurrent cancer [39].”
• Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. (2010, methodology): “(B) Biochemical failure by Phoenix criteria.(15) GyE, Gray equivalents.”
• Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. (2017, neutral): “Diabetes 99 (16) 107 (18) Bowel disorder 21 (3) 19 (3) Bladder disorder 14 (2) 15 (3) Medical history within 5 years* Cardiac 337 (55) 342 (57) Respiratory 73 (12) 59 (10)”
• Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. (2011, background): “0 ng/mL or more above the nadir in men who underwent radiation.(17) Men with less than 1 year of follow-up after treatment were not included in the analysis.”
• EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. (2020, methodology): “After primary RT with or without short-term hormonal manipulation, the Radiation Therapy Oncology Group (RTOG) and the American Society for Radiation Oncology Phoenix Consensus Conference definition of PSA failure (with an accuracy of >80% for clinical failure) is any PSA increase of 2 ng/mL higher ”
• Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. (2008, background): “in regression analysis comparing definitions, and eliminates backdating (2).”